Indaptus Therapeutics, Inc.
INDP
$2.56
$0.5326.31%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -5.29% | 213.93% | -32.53% | -4.40% | -25.10% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -52.77% | 95.51% | -15.71% | 8.47% | 15.96% |
| Operating Income | 52.77% | -95.51% | 15.71% | -8.47% | -15.96% |
| Income Before Tax | 43.93% | -96.38% | 3.06% | -30.22% | -19.06% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 43.93% | -96.38% | 3.06% | -30.22% | -19.06% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 43.93% | -96.38% | 3.06% | -30.22% | -19.06% |
| EBIT | 52.77% | -95.51% | 15.71% | -8.47% | -15.96% |
| EBITDA | -- | -95.50% | 15.72% | -8.46% | -15.98% |
| EPS Basic | 97.45% | 57.36% | 66.98% | 30.88% | 27.88% |
| Normalized Basic EPS | 97.45% | 57.36% | 66.98% | 30.88% | 27.88% |
| EPS Diluted | 97.45% | 57.36% | 66.98% | 30.88% | 27.88% |
| Normalized Diluted EPS | 97.45% | 57.36% | 66.98% | 30.88% | 27.88% |
| Average Basic Shares Outstanding | 2,101.02% | 360.53% | 193.49% | 88.43% | 65.11% |
| Average Diluted Shares Outstanding | 2,101.02% | 360.53% | 193.49% | 88.43% | 65.11% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |